Synthon Biopharmaceuticals is an international biotech company, located at its proprietary state-of-the-art R&D and manufacturing campus in Nijmegen, the Netherlands. Synthon Biopharmaceuticals was originally founded as a member of the Synthon Group. The Group’s success in the field of complex generic medicines had been a stimulus to start development of its own biopharmaceuticals franchise in 2007.
Since 2019, Synthon Biopharmaceuticals has been continuing its journey as a privately-owned, standalone company, with highly focused development activities for new molecular entities, including antibody-drug conjugates, in two key therapeutic areas: oncology and autoimmune diseases. The company is building a promising portfolio of next generation medicines for patients in areas with a high unmet medical need.
2007: Launch of biopharmaceuticals business within Synthon Group
2011: Opened new biopharmaceutical laboratories in Nijmegen, NL
2011: Acquired Syntarga in the Netherlands
2012: Licensed biosimilar trastuzumab to Amgen/Watson (now: Amgen/Actavis)
2013: New antibody-drug conjugation (ADC) facility operational in Nijmegen, NL
2014: New monoclonal antibody production (mAb) facility established in Nijmegen, NL
2014: Start treatment of First Patients in Phase I Trial with anti-HER2 ADC SYD985
2017: Initiation of the pivotal Phase III TULIP trial® with SYD985
2018: U.S. FDA Fast Track designation for [vic-]trastuzumab duocarmazine (SYD985)